Cudarolimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade from ProteoGenix; catalogue PX-TA1651; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cudarolimab Biosimilar is a monoclonal antibody (mAb) that targets and inhibits the activity of tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40. It is a biosimilar version of Cudarolimab, a therapeutic antibody currently in clinical development for the treatment of various cancers.
Cudarolimab Biosimilar is a recombinant humanized IgG1 mAb, with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to TNFRSF4, while the constant region plays a role in immune effector functions.
TNFRSF4 is a co-stimulatory molecule that is expressed on the surface of activated T cells. It plays a critical role in regulating T cell activation and survival, and its dysregulation has been implicated in the development and progression of various cancers. Cudarolimab Biosimilar binds to TNFRSF4 and blocks its interaction with its ligand, OX40L, thereby inhibiting downstream signaling pathways that promote T cell proliferation and survival.
In addition to its direct effect on T cells, Cudarolimab Biosimilar also has an indirect anti-tumor activity through its ability to modulate the tumor microenvironment. By blocking TNFRSF4 signaling, the antibody can inhibit the recruitment and activation of immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, and promote the infiltration of effector T cells into the tumor.
Cudarolimab Biosimilar is being developed as a potential treatment option for various types of cancer, including solid tumors and hematological malignancies. It is currently in preclinical development, with plans for clinical trials in the near future.
As a biosimilar, Cudarolimab Biosimilar offers a more affordable and accessible alternative to the originator antibody, Cudarolimab. This can potentially increase patient access to this targeted therapy and improve treatment outcomes.
In addition, the unique mechanism of action of Cudarolimab Biosimilar, targeting the TNFRSF4 pathway, may offer a novel approach for the treatment of cancers that are resistant to current therapies. It also has the potential to be used in combination with other cancer treatments, such as chemotherapy and immune checkpoint inhibitors, to enhance their efficacy.
In summary, Cudarolimab Biosimilar is a promising therapeutic antibody that targets TNFRSF4, a key co-stimulatory molecule involved in T cell activation and survival. Its unique mechanism of action and potential for use in combination with other cancer treatments make it a promising candidate for the treatment of various cancers. With ongoing preclinical development and plans for clinical trials, Cudarolimab Biosimilar has the potential to make a significant impact in the field of cancer therapy.
ProteoGenix catalogue number PX-TA1651. For research use only.
Target: Cudarolimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cudarolimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
